SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense investor debate as the stock experiences after-hours volatility despite delivering a record-breaking earnings beat and bullish revenue guidance fueled by massive AI memory demand. While some community members are calling the price action a manipulative shakeout designed to flush retail traders, others are warning that the rapid year-to-date gains have left the stock overextended and vulnerable to a broader sector correction.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. (SWMR) is surging following its recent IPO as retail investors capitalize on the stock's low float, autonomous drone technology, and high-profile industry associations. The community is heavily focused on the stock's intense volatility and potential for further gains, with intense debates unfolding between bullish traders chasing a squeeze and skeptics wary of the company's limited revenue and valuation.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community debates whether recent delivery momentum and potential chip-unit partnerships can sustain a breakout above key resistance levels. Discussions are heavily divided between bullish sentiment regarding the company's long-term energy ecosystem and cautious traders skeptical of market manipulation and the broader macroeconomic impact on Chinese ADRs.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as Middle East geopolitical instability, specifically the closure of Qatar's Ras Laffan facility and ongoing disruptions in the Strait of Hormuz, positions the company as a critical beneficiary due to its high spot market exposure. Investors are actively discussing the potential for a massive EBITDA windfall, while community sentiment remains focused on the stock's long-term growth trajectory and the strategic importance of its expanding LNG production capacity.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

NextDecade is currently trending due to active accumulation by institutional players like Hanwha, who have been building a significant stake even as the stock trades at levels well below recent highs. The community is heavily focused on the project's long-term potential as an essential global LNG supplier, often debating the company's valuation models, upcoming expansion milestones, and the ongoing structural shift toward secure energy infrastructure.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is currently trending as investors debate its long-term sustainability amidst a broader market correction and upcoming protocol updates. The community remains divided, with many highlighting its role as a key liquidity hub on the Base chain, while others express caution regarding token dilution and correlation with Bitcoin's volatility.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is currently a focal point for investors following strong quarterly earnings, reaffirmed multi-hundred percent revenue growth guidance, and the successful securing of significant defense contracts for missile propulsion and autonomous swarm technology. Community discussion remains heavily divided between retail investors capitalizing on the stock's high short interest for a potential squeeze and those focused on the long-term potential of the firm's pivot into integrated defense manufacturing.

NextNav, Inc. develops next-generation positioning, navigation, and timing solutions. Through its Pinnacle system, it provides floor-level altitude service to devices with a barometric pressure sensor. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNav is currently capturing significant market interest as investors closely monitor the potential for an FCC Notice of Proposed Rulemaking (NPRM) regarding its terrestrial positioning, navigation, and timing (PNT) spectrum assets. The community is actively debating the stock's valuation, the impact of potential warrant exercises, and the strategic importance of the 900 MHz band, while balancing optimism over the regulatory timeline against technical resistance levels.

Cheniere Energy, Inc. engages in liquefied natural gas (LNG) related businesses. It owns and operates LNG terminals, develops, constructs, and operates liquefaction projects near Corpus Christi, Texas, and at the Sabine Pass LNG terminal. The company was founded by Charif Souki in 1996 and is headquartered in Houston, TX.

Cheniere Energy Inc.

Cheniere Energy (LNG) is trending as natural gas markets react to significant supply disruptions in the Middle East, with facilities in Iran and Qatar sustaining damage that threatens nearly one-fifth of global LNG capacity. The community is actively debating the stock's role as a strategic energy play, with many investors pointing to Cheniere's position as a dominant U.S. exporter as a crucial solution for energy-hungry European and Asian markets facing potential long-term shortages.

FLEX LNG Ltd. engages in the seaborne transportation of liquefied natural gas (LPG) through the ownership and operation of LNG carriers. The company was founded by Philip Eystein Fjeld, Trym Tveitnes, and Jostein Ueland in September 2006 and is headquartered in Hamilton, Bermuda.

Flex Lng Ltd

Flex LNG is drawing attention from investors as a key player in global energy transit, with community members closely tracking potential upside linked to its robust dividend yields and ongoing charter extensions. While some traders are focused on the stock's role in the shifting global energy landscape, others are monitoring technical chart patterns and assessing the long-term impact of its contract structures on future stability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Icotyde was jointly discovered by Protagonist and Johnson &amp; Johnson but it will now be commercialized by Johnson &amp; Johnson alone under a license and collaboration agreement established in 2017.&nbsp;</li><li>H.C. Wainwright analyst Douglas Tsao said that while Icotyde's approval was expected, the earlier than expected approval and "clean" label represent upside surprises.</li><li>Clear Street raised the firm's price target on Protagonist Therapeutics to $104 from $91 and kept a ‘Buy’ rating on the shares following the FDA approval of Icotyde.</li></ul><p>Wall Street on Wednesday reiterated confidence in Protagonist Therapeutics (PTGX) after John and Johnson received U.S. Food and Drug Administration’s approval for Icotyde for the treatment of moderate-to-severe plaque psoriasis.</p><p>The FDA approved the drug in adults and pediatric patients 12 years of age and older. The approval was based on four late-stage studies that met all primary endpoints and demonstrated a favorable safety profile in 2,500 patients.</p><h2 class="st-heading-2">Protagonist’s Role In Icotyde</h2><p>Icotyde was jointly discovered by Protagonist and Johnson &amp; Johnson but it will now be commercialized by Johnson &amp; Johnson alone under a license and collaboration agreement established in 2017.</p><p>FDA approval of Icotyde triggers a $50 million milestone payment to Protagonist, the company said, while adding that it is eligible eligible to receive up to $580 million in potential additional regulatory and sales milestone payments, as well as tiered royalties ranging from 6% to 10% on global net sales.</p><h2 class="st-heading-2">Analyst Take</h2><p>H.C. Wainwright analyst Douglas Tsao said that while Icotyde's approval was expected, the earlier than expected approval and "clean" label represent upside surprises. Johnson &amp; Johnson is committed to building Icotyde into a blockbuster, which should create "significant value" for Protagonist Therapeutics (PTGX), the analyst told investors in a research note.</p><p>H.C. Wainwright believes Icotyde is positioned to "transform the plaque psoriasis landscape with a differentiated label that highlights its superior efficacy and safety profile." The firm reiterated a ‘Buy’ rating on Protagonist with a $117 price target.</p><p>Clear Street raised the firm's price target on Protagonist Therapeutics to $104 from $91 and kept a ‘Buy’ rating on the shares following the FDA approval of Icotyde. The approval transitions Protagonist into a company with royalty-bearing commercial exposure, while retaining upside from lifecycle expansion and the broader pipeline, the firm said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around PTGX stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/PTGX">PTGX stock</a> has gained 78% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fed-chair-powell-says-iran-war-will-spike-inflation-in-the-near-term-but-too-soon-to-assess-impact/cZ37Nb9RIW5">Fed Chair Powell Says Iran War Will Spike Inflation In The Near Term, But Too Soon To Assess Impact</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Global stock market chart and trading board - stock photo

Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics

The FDA approved the drug for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older on Wednesday. 

Equity

The FDA approved the drug for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older on Wednesday. 


Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's Why

Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 52-Week High - What's Next...

Protagonist Therapeutics, Inc. $PTGX Holdings Boosted by HighVista Strategies LLC

HighVista Strategies LLC increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 110.3% in the third quarter, according to its most recent 13F filing with the...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fourteen brokerages that are covering the stock, MarketBeat Ratings reports...

Protagonist Therapeutics, Inc. $PTGX Stock Holdings Lifted by Boxer Capital Management LLC

Boxer Capital Management LLC grew its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 83.3% during the 3rd quarter, according to the company in its most recent filing with...

Commodore Capital LP Decreases Stock Position in Protagonist Therapeutics, Inc. $PTGX

Commodore Capital LP lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 4.7% in the third quarter, according to the company in its most recent Form 13F...

Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Mangrove Partners IM LLC

Mangrove Partners IM LLC lifted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 21.0% during the third quarter, according to its most recent disclosure with...

Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday

Protagonist Therapeutics (NASDAQ:PTGX) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 18. (View Earnings Report at...

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High - Should You Buy?

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's Why...

Intech Investment Management LLC Sells 12,310 Shares of Protagonist Therapeutics, Inc. $PTGX

Intech Investment Management LLC cut its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 36.3% during the third quarter, according to its most recent 13F filing with the...

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

PTGX
Protagonist Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PTGX News

PTGXProtagonist Therapeutics Inc